Navigation Links
Sentillion and Healthland Create New Efficiencies for Community Hospitals
Date:6/24/2009

e total ownership and control of how SSO is deployed and maintained hospital-wide through an extremely practical and cost effective "Do It Yourself" approach.

"At Healthland, we are focused on providing the technology that enables community and critical access hospitals to provide the highest quality of healthcare," said Angie Franks, Healthland Senior Vice President of Sales and Marketing. "For us, it's about creating operational efficiencies and reducing costs, allowing rural healthcare providers to do what they do best - care for their patients. Sentillion's technology is a great fit for Healthland and the goals we are working to achieve in healthcare IT. We are pleased to partner with this impressive organization."

About Sentillion

Since 1998, Sentillion has been revolutionizing healthcare IT with award winning, industry recognized identity and access management technology. Sentillion has successfully combined patented technology with a deep understanding of the healthcare industry to deliver the most comprehensive set of solutions for single sign-on, identity management, clinical workstations and desktop virtualization. Recognized as the number one single sign-on (SSO) vendor in the KLAS Top 20: 2008 Year-End Report, Sentillion is the only identity and access management company whose solutions are used daily by over 400,000 caregivers in leading healthcare organizations across North America and Europe. Sentillion is a privately held company headquartered in Andover, Mass. For more information, visit Sentillion at www.sentillion.com.

About Healthland:

Founded in 1980, Healthland (formerly Dairyland Healthcare Solutions) is America's market leader of IT solutions to small community and critical access hospitals. Committed exclusively to this market, Healthland software and services empower small
'/>"/>

SOURCE Sentillion
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sentillion Releases Healthcare Do It Yourself Tool for Single Sign-On and Context Management Application Interfaces
2. Sentillion Introduces Advanced Authentication Solution For Direct Access to Cerner, Eclipsys, Epic, McKesson and MEDITECH Applications
3. Sentillion Announces 2008 as the Best Year in the Companys History
4. Sentillion Appoints New UK Sales Manager
5. Sentillion and Baptist Health System to Speak at Upcoming Gartner Identity & Access Management Summit
6. Baptist Health System Deploys Sentillions Vergence Solution to Provide Secure Identity and Access Management to 3,000 Clinicians
7. Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning
8. Duke University Health System to Implement Clinically Optimized, Advanced Authentication Solution From Sentillion
9. Sentillion Receives U.S. Patent for Administering Context Management Systems
10. Sentillion Ranked #1 Vendor in KLAS Single Sign-On & Context Management Report
11. iSOFT Offers Healthcare Single Sign-On Solutions After Agreement with Sentillion
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 2Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 3Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 4Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 5Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 6Health News:Heart Hormones Beat Back Cancers in Mice 2Health News:Heart Hormones Beat Back Cancers in Mice 3Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 2Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 3Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 4Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 5Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 6Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 2Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 3Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 4Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 5Health News:Plastic Surgeon Joins Established Practice 2
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 1Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 2Midlife Heart Risk Factors Linked to Later Dementia 53613 1Midlife Heart Risk Factors Linked to Later Dementia 53613 2Midlife Heart Risk Factors Linked to Later Dementia 53613 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4